Human medicines European public assessment report (EPAR): Doptelet, avatrombopag, Date of authorisation: 20/06/2019, Revision: 12, Status: Authorised

Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - May 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 May 2026, 15:00 (CEST) to 13 May 2026, 16:00 (CEST)

Product Management Service (PMS) information day 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 9 June 2026, 08:45 (CEST) to 9 June 2026, 17:00 (CEST)

Product Management Service (PMS) roadmap

Decision of EMA on adoption by analogy of Commission decision C(2026) 634 final of 5 February 2026 amending Decision C(2002) 98 fixing rates of daily subsistence allowances and ceilings for reimbursements of hotel expenses for missions outside EU

Human medicines European public assessment report (EPAR): Iloperidone Vanda Pharmaceuticals, iloperidone, Date of refusal: 12/06/2026, Status: Refused

Human medicines European public assessment report (EPAR): Ibuprofen Gen.Orph, ibuprofen, Date of authorisation: 16/02/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Dazublys, trastuzumab, Date of authorisation: 30/06/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Reyataz, atazanavir sulfate, Date of authorisation: 01/03/2004, Revision: 58, Status: Authorised

Annual activity report 2024